In patients with metastatic gastroenteropancreatic neuroendocrine tumors (NETs), we
evaluated health-related quality of life (HRQoL) from the first peptide receptor radionuclide …

Abstract Introduction Neuroendocrine tumors (NETs) have proven to be appropriate
neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow …

BACKGROUND Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-
growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract (GI-NETs) …

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare neoplasms capable of
producing hormones. The development of new treatments has improved progression-free …

Objectives There is convincing evidence that peptide receptor radionuclide therapy (PRRT)
using 177 Lu-DOTATATE compared to octreotide therapy has a positive effect on overall …

Materials and methods A total of 46 patients with refractory or progressive symptomatic GEP-
NETs (previously treated at various stages with long-acting octreotide, chemotherapy …

The aim of the current study was to describe the risk of hepatotoxicity for patients with
gastroenteropancreatic neuroendocrine tumors undergoing peptide receptor radionuclide …

Background Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rare cancers
most often found in the gastrointestinal system or the pancreas. However, patient-reported …

Peptide receptor radionuclide therapy (PRRT) may induce long-term toxicity to the bone
marrow (BM). The aim of this study was to analyze persistent hematologic dysfunction (PHD) …

Outcome analyses for patients with gastroenteropancreatic neuroendocrine tumors (GEP
NET) after peptide receptor radionuclide therapy (PRRT) are still limited, especially with …